Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-31: Phase II open-label randomized study of nivolumab in advanced melanoma
jRCT2080223054Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in melanoma (2 arms), sponsored by Ono Pharmaceutical. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2080223054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223054.